Abstract
PurposeTo assess the efficacy of different preventive dental visits and treatments in reducing the risk of medication-related osteonecrosis of the jaws (MRONJ).MethodsIn this retrospective study, patients diagnosed with MRONJ were divided into 5 groups based on available data: no preventive dental visits (group 0); dental visits and compliance with recommended treatments, at the university hospital’s dental clinic (group 1) or maxillofacial surgery unit (group 2), or at a private dentist’s (group 3); dental visits at one of the above and noncompliance with proposed treatments (group 4); patients judged eligible by the oncologist on panoramic radiography (group 5). Patients were classified on severity of MRONJ according to the Italian SIPMO/SICMF 2.0 staging system. A descriptive analysis was performed on the results. Fisher’s exact test was applied (p < 0.05).ResultsNinety-three patients diagnosed with MRONJ were considered for the study, but 22 were excluded due to a lack of data, leaving a sample of 71 cases. MRONJ staging was only 0 for some patients (26.92%) in group 0. In all groups, the majority of patients had stage 2 MRONJ. The proportions of cases in stage 3 were 7.69% in group 0, 18.18% in group 3, and 43.48% in group 5. Groups 0 and 3 were somewhat similar as regard MRONJ staging. Most patients in group 5 had MRONJ stage 2 or 3. No statistically significant differences emerged between the groups.ConclusionsPreventive dental care can reduce the risk of MRONJ providing patients comply with the specialist’s recommendations.
Highlights
Medication-related osteonecrosis of the jaw bones (MRONJ) is one of the most debated diseases in dentistry. This adverse event was initially described as bisphosphonate-related osteonecrosis of the jaws (BRONJ) [1], but since 2010, there have been reports of this condition in patients taking other
Ninety-three patients diagnosed with medication-related osteonecrosis of the jaws (MRONJ) were considered for the study, but 22 were excluded due to a lack of data, leaving a sample of 71 eligible patients: 50 females (70.42%) and 21 males (29.58%), with a mean age of 68.7 years
The aims of the present study were to assess the efficacy of preventive dental care, and to establish whether clinicians conducting preventive dental visits can play a role in reducing or increasing the risk of MRONJ
Summary
Medication-related osteonecrosis of the jaw bones (MRONJ) is one of the most debated diseases in dentistry. This adverse event was initially described as bisphosphonate-related osteonecrosis of the jaws (BRONJ) [1], but since 2010, there have been reports of this condition in patients taking other. Two classification systems are used in Italy nowadays to stage the disease: the AAOMS [3]; and the SICMFSIPMO [4, 9]. No evidence of exposed or necrotic bone in patients who have been treated with bisphosphonates Nonspecific clinical findings and symptoms such as jaw pain or osteosclerosis, but no clinical evidence of exposed bone
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
